Andrx Drops Cardura XL Distribution Deal In Move Away From Brand Business
This article was originally published in The Pink Sheet Daily
Executive Summary
Company moves to terminate a supply and distribution deal with Pfizer because the BPH agent failed to receive FDA approval by Dec. 31, 2004. Andrx is divesting its brand business to focus on its "core competencies" of controlled-release formulation development and distribution.